AAV-MyoAAV 4E vector system (AAV-MyoAAV 4E expression system, AAV-MyoAAV 4E packaging plasmid system) (Amp and Kanamycin) (GeneMedi Owned)

GeneMedi (GM) AAV-MyoAAV 4E Vector system is including: 1) AAV-MyoAAV 4E Rep-Cap plasmid (AAV-MyoAAV 4E-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).

You can produce AAV-MyoAAV 4E particle in 293T cell line in high titer using GeneMedi's AAV-MyoAAV 4E Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

MyoAAV4E can be considered as a new evolutionary form of MyoAAV4A with possible overloading of the properties, for example, enshrine improved characteristics, including transduction efficiency, uptake to specific muscle tissue or reduced sensitivity to the immune system. This variant might employ both capsid alterations and distinct promoter/enhancer motifs to deliver genes and accomplish transcription solely in muscle cells.

GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.

Go to AAV vector system >>